000254317 000__ 05194cam\a2200385\a\45e0
000254317 001__ 254317
000254317 005__ 20210513095500.0
000254317 008__ 020128s2001\\\\mdua\\\\\b\\\\100\0\eng\c
000254317 020__ $$a0198515952
000254317 035__ $$a(OCoLC)ocm48879153
000254317 035__ $$a254317
000254317 040__ $$aVAM$$cVAM$$dGPO$$dVET$$dNLM$$dGPO$$dLVB$$dGPO$$dSYB$$dZQM
000254317 042__ $$apcc
000254317 049__ $$aISEA
000254317 050_4 $$aRC261.A1$$bJ68 no.30 2001$$aRC271.A35
000254317 074__ $$a0507-L
000254317 074__ $$a0507-L (online)
000254317 0860_ $$aHE 20.3162/3:30
000254317 1112_ $$aNational Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer$$d(2000 :$$cBethesda, Md.)
000254317 24514 $$aThe National Institutes of Health Consensus Development Conference :$$badjuvant therapy for breast cancer : Bethesda, Maryland, November 1-3, 2000 /$$cconference sponsors, National Cancer Institute, National Institutes of Health Office of Medical Applications of Research ; co-sponsors, National Institute of Nursing Research, National Institutes of Health Office of Research on Women's Health.
000254317 24630 $$aAdjuvant therapy for breast cancer
000254317 260__ $$a[Bethesda, MD] :$$bNational Institutes of Health,$$c2001.
000254317 300__ $$a152 p. :$$bill. ;$$c28 cm.
000254317 440_0 $$aJournal of the National Cancer Institute.$$pMonographs,$$x1042-6773 ;$$vno. 30
000254317 500__ $$aShipping list no.: 2002-0080-P.
000254317 5050_ $$aMonograph overview / Jeffrey S. Abrams, Patricia Eifel -- National Institutes of Health Consensus Development Conference statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 / National Institutes of Health Consensus Development Panel -- Adjuvant therapy for breast cancer: current controversies and future prospects / William C. Wood -- Interpreting and integrating risk factors for patients with primary breast cancer / Gary M. Clark -- Traditional and newer pathologic factors / Stuart J. Schnitt -- Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer / Maria Grazia Daidone, Rosella Silvestrini -- Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women / James J. Dignam -- Adjuvant therapy for very young women with breast cancer: need for tailored treatments / Aron Goldhirsch ... [et al.] -- Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status / Hyman B. Muss -- Duration of adjuvant tamoxifen therapy / John Bryant, Bernard Fisher, James Dignam -- Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in Stage 1 breast cancer / Bernard Fisher ... [et al.] -- Ovarian ablation as adjuvant therapy for breast cancer / Nancy E. Davidson -- Progress in systemic chemotherapy of primary breast cancer: an overview / Gabriel N. Hortobagyi -- Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes / Peter Marcus Ravdin -- Is Her-2/neu a predictor of anthracycline utility? No / George W. Sledge, Jr. -- Texanes in the adjuvant treatment of breast cancer: why not yet? / Martine J. Piccart ... [et al.] -- Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 / Norman Wolmark ... [et al.] -- Who should not receive adjuvant chemotherapy?: international databases / Jonas Bergh, Marit Holmquist -- Who should not receive chemotherapy?: data from American databases and trials / Monica Morrow, Helen Krontiras -- Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer / Karen H. Antman -- Treatment guidelines and techniques in delivery of postmastectomy radiotherapy in management of operable breast cancer / Lori J. Pierce -- Side effects, quality-of-life issues, and trade-offs: the patient perspective / Amy S. Langer -- Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life / Patricia A. Ganz -- Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer / Ann H. Partridge, Harold J. Burstein, Eric P. Winer -- Decision-making process, communicating risk/benefits: is there an ideal technique? / Mark Levine, Tim Whelan -- Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? / R. John Simes, Alan S. Coates.
000254317 650_0 $$aBreast$$xTumors$$xChemotherapy.
000254317 650_0 $$aTamoxifen.
000254317 650_0 $$aAnthracyclines.
000254317 7102_ $$aNational Cancer Institute (U.S.)
000254317 7102_ $$aNational Institutes of Health (U.S.).$$bOffice of Medical Applications of Research.
000254317 7102_ $$aNational Institute of Nursing Research (U.S.)
000254317 7102_ $$aNational Institutes of Health (U.S.).$$bOffice of Research on Women's Health.
000254317 77608 $$iOnline version:$$aNational Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer (2000 : Bethesda, Md.)$$tNational Institutes of Health Consensus Development Conference.$$d[Bethesda, MD] : National Institutes of Health, 2001$$w(OCoLC)622659854
000254317 85200 $$bgen$$hRC271.A35$$iN38$$i2001
000254317 85640 $$zOnline access$$uhttp://catalog.hathitrust.org/api/volumes/oclc/48879153.html
000254317 909CO $$ooai:library.usi.edu:254317$$pGLOBAL_SET
000254317 980__ $$aBIB
000254317 980__ $$aBOOK
000254317 983__ $$aOnline